Maze Therapeutics (MAZE) Share-based Compensation (2024 - 2026)

Maze Therapeutics has disclosed Share-based Compensation across 3 years of filings, most recently posting $7.1 million for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $7.1 million, up 120.37% year-over-year; the trailing twelve-month figure through Mar 2026 was $20.3 million (up 92.04% YoY), and the FY2025 annual result was $16.4 million, up 70.02% from the prior year.
• Share-based Compensation came in at $7.1 million for Q1 2026 at Maze Therapeutics, up from $6.1 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $7.1 million in Q1 2026 to a low of $2.1 million in Q2 2024.
• The 3-year median for Share-based Compensation is $3.2 million (2025), against an average of $3.7 million.
• Across the five-year window, Share-based Compensation surged 39.65% in 2025 and soared 120.37% in 2026, its largest moves.
• Maze Therapeutics' Share-based Compensation stood at $2.9 million in 2024, then surged by 113.01% to $6.1 million in 2025, then climbed by 17.06% to $7.1 million in 2026.
• The last three Share-based Compensation figures came in at $7.1 million (Q1 2026), $6.1 million (Q4 2025), and $3.9 million (Q3 2025), per Business Quant data.